Show simple item record

dc.contributor.authorDrevets, Wayne C
dc.contributor.authorWittenberg, Gayle M
dc.contributor.authorBullmore, Edward T
dc.contributor.authorManji, Husseini K
dc.date.accessioned2022-02-19T02:02:36Z
dc.date.available2022-02-19T02:02:36Z
dc.date.issued2022-03
dc.identifier.issn1474-1776
dc.identifier.otherPMC8763135
dc.identifier.other35039676
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/334220
dc.description.abstractOver the past two decades, compelling evidence has emerged indicating that immune mechanisms can contribute to the pathogenesis of major depressive disorder (MDD) and that drugs with primary immune targets can improve depressive symptoms. Patients with MDD are heterogeneous with respect to symptoms, treatment responses and biological correlates. Defining a narrower patient group based on biology could increase the treatment response rates in certain subgroups: a major advance in clinical psychiatry. For example, patients with MDD and elevated pro-inflammatory biomarkers are less likely to respond to conventional antidepressant drugs, but novel immune-based therapeutics could potentially address their unmet clinical needs. This article outlines a framework for developing drugs targeting a novel patient subtype within MDD and reviews the current state of neuroimmune drug development for mood disorders. We discuss evidence for a causal role of immune mechanisms in the pathogenesis of depression, together with targets under investigation in randomized controlled trials, biomarker evidence elucidating the link to neural mechanisms, biological and phenotypic patient selection strategies, and the unmet clinical need among patients with MDD.
dc.description.sponsorshipJohnson and Johnson
dc.languageeng
dc.publisherSpringer Science and Business Media LLC
dc.sourcenlmid: 101124171
dc.sourceessn: 1474-1784
dc.titleImmune targets for therapeutic development in depression: towards precision medicine.
dc.typeArticle
dc.date.updated2022-02-19T02:02:35Z
prism.publicationNameNat Rev Drug Discov
dc.identifier.doi10.17863/CAM.81633
dcterms.dateAccepted2021-11-09
rioxxterms.versionofrecord10.1038/s41573-021-00368-1
rioxxterms.versionVoR
dc.contributor.orcidBullmore, Edward T [0000-0002-8955-8283]
dc.identifier.eissn1474-1784
pubs.funder-project-idWellcome Trust (104025/Z/14/Z)
pubs.funder-project-idMedical Research Council (MC_G0802534)
pubs.funder-project-idMedical Research Council (MR/L014815/1)
cam.issuedOnline2022-01-17


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record